Fundraising Fox
🦊/People
Sign in

Rob Hopfner

Investor

RPh, PhD, MBA at Pivotal Life Sciences · Board director at Plexium · Board director at Inozyme Pharma · Board director at Civitas Therapeutics

San Francisco, California, United States

Find your path to Rob

157 people in our graph share verified history with Rob — schools, employers, funds. One of them is your warm intro.

Ian PeikonunlockedRob: together at Plexium (2022–2025)
×2Rob: together at Vaxcyte
×2Rob: together at Plexium
Rob: together at Evommune

About

Rob Hopfner joined Pivotal Life Sciences in 2017 and has experience across venture investing stages, from early/seed company building to later-stage private and public investing in the life sciences. He was previously a Managing Director at Bay City Capital and earlier worked in DuPont/Merck Pharmaceuticals' Business Development & Strategy group. He holds an RPh in Pharmacy and a PhD in Pharmacology from the University of Saskatchewan, an MBA from the University of Chicago Booth School of Business, and completed post-doctoral work at Harvard Medical School.

Contact· self-published, not guessed

Invests in

BiotechHealthtechMedical Devices

Board director at Plexium

Intro paths

→

In turn, Rob can intro founders to Plexium's investors below.

Plexium's investors · 9

CRV (Charles River Ventures)Bay Area · $250K – $5M checks · since 2025DCVC (Data Collective)Palo Alto · $5M – $25M checks · since 2025Lux CapitalNew York · $100K – $100M checks · since 2021M VenturesLos Angeles · $10.8M checks · since 2025Neotribe VenturesMenlo Park · $250K – $2M checks · since 2025Pivotal Life SciencesSan Francisco · since 2025SoftBank Vision FundLondon · since 2025TCG CrossoverPalo Alto · since 2025The Column GroupSan Francisco · $30M checks · since 2025

Board director at Inozyme Pharma

Intro paths

→

In turn, Rob can intro founders to Inozyme Pharma's investors below.

Inozyme Pharma's investors · 5

Longitude CapitalMenlo Park · $10M – $30M checksNew Enterprise Associates (NEA)Menlo Park · $200K – $40M checksPivotal Life SciencesSan FranciscoSanofi VenturesCambridge · $5M checksSofinnova VenturesMenlo Park · $100K – $15M checks

Co-founders at Inozyme Pharma

ABAxel Bolte
Axel BolteExecutive Officer, Director

Board director at Civitas Therapeutics

Intro paths

→

In turn, Rob can intro founders to Civitas Therapeutics's investors below.

Civitas Therapeutics's investors · 6

Bay City CapitalSan Rafael · $5M – $10M checks · since 2014Canaan PartnersStamford · $500K – $20M checks · since 2014Longitude CapitalMenlo Park · $10M – $30M checks · since 2014OrbiMedNew York · $1M – $75M checks · since 2014RA CapitalBoston · since 2014Sofinnova VenturesMenlo Park · $100K – $15M checks · since 2014

Co-founders at Civitas Therapeutics

RB
RICHARD BATYCKYExecutive Officer
GB
GLENN BATCHELDERDirector

Experience

  1. Pivotal bioVenture PartnersManaging Partnercurrent2017 — presentSan Francisco
  2. Pivotal bioVenture PartnersExecutive Committeecurrent2022 — presentSan Francisco, California, United States
  3. LAND TherapeuticsBoardcurrent2024 — presentBoston, Massachusetts, United States
  4. EvommuneBoardcurrent2020 — presentPalo Alto, California, United States
  5. PlexiumBoardcurrent2021 — presentSan Diego, California, United States
  6. Inozyme PharmaBoard2019 — 2025Boston, Massachusetts, United States
  7. OculisBoard2017 — 2023Lausanne, Vaud, Switzerland
  8. VaxcyteBoard2017 — 2021Foster City, California, United States
  9. Bay City Capital LLCManaging Director and Partner2009 — 2017San Francisco, CA
  10. Bay City Capital LLCPrincipal2006 — 2009San Francisco, CA
  11. Vtesse, Inc.Board2015 — 2017
  12. Civitas TherapeuticsBoard2013 — 2014Boston, Massachusetts, United States
  13. Dermira, Inc.Board2010 — 2014Palo Alto, California, United States
  14. Aciex Therapeutics, Inc.Board2007 — 2014Andover, Massachusetts, United States
  15. Hyperion TherapeuticsBoard2009 — 2013South San Francisco, California, United States
  16. PTC Therapeutics, Inc.Board2005 — 2013Warren, New Jersey, United States
  17. NextWave TherapeuticsBoard2010 — 2012Palo Alto, California, United States

Skills & more

Venture Capital21Corporate Development10Due Diligence10Start-ups5Biotechnology8Technology Transfer2Healthcare3Drug Discovery1Lifesciences3Investments2Private Equity2Commercialization2
+6 moreEntrepreneurshipBusiness PlanningStrategic PartnershipsLife SciencesStrategyPharmaceutical Industry

From Rob's professional profile.

Deals · 2

PlexiumBoard seat

via Pivotal Life Sciences · filed Aug 2025 · $60.1M raise

SutroVaxBoard seat

via Pivotal Life Sciences · filed Apr 2020 · $110M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

EvommuneLAND TherapeuticsOculisRallybioVaxcyte

Investor

Aciex TherapeuticsArcutis TherapeuticsAvalyn PharmaCivitas TherapeuticsDermiraEvommuneExscientiaGracellHyperion TherapeuticsInozymeKaruna TherapeuticsLB PharmaMadrigal PharmaceuticalsMerus BVNextWave PharmaceuticalsOculisRallybio, LLC

Sources: the firm's website · SEC Form D filings · curated public sources.

Colleagues at Pivotal Life Sciences

AJ Velasquez-Mao
Associate at Dolby Family Ventures
Ash Khanna
Partner at Pivotal bioVenture Partners
Benjamin Li
Vice President at Pivotal Life Sciences
Brian Mills
Vice President at Pivotal Life Sciences
Glenn Batchelder
Venture Partner at Pivotal Life Sciences
Jeni Lee
Partner at Pivotal Life Sciences
Kin Ho Kwok
General Partner at Pivotal Life Sciences
Lisa Marrone
Investor at Pivotal bioVenture Partners

Frequently asked questions

Who is Rob Hopfner?
Rob Hopfner joined Pivotal Life Sciences in 2017 and has experience across venture investing stages, from early/seed company building to later-stage private and public investing in the life sciences. He was previously a Managing Director at Bay City Capital and earlier worked in DuPont/Merck Pharmaceuticals' Business Development & Strategy group. He holds an RPh in Pharmacy and a PhD in Pharmacology from the University of Saskatchewan, an MBA from the University of Chicago Booth School of Business, and completed post-doctoral work at Harvard Medical School.
Where does Rob Hopfner work?
Rob Hopfner is RPh, PhD, MBA at Pivotal Life Sciences and Board director at Plexium and Board director at Inozyme Pharma and Board director at Civitas Therapeutics.
What does Rob Hopfner invest in?
Rob Hopfner invests in Biotech, Healthtech, Medical Devices.
What boards does Rob Hopfner sit on?
Rob Hopfner holds tracked board seats at Evommune, LAND Therapeutics, Oculis, Plexium, Plexium, Rallybio, SutroVax, Vaxcyte.
What companies has Rob Hopfner invested in?
Investments tracked here include Aciex Therapeutics, Arcutis Therapeutics, Avalyn Pharma, Civitas Therapeutics, Dermira, Evommune, Exscientia, Gracell, Hyperion Therapeutics, Inozyme, Karuna Therapeutics, LB Pharma, and 6 more.
Where did Rob Hopfner go to school?
Rob Hopfner studied at The University of Chicago Booth School of Business (MBA, Finance); Harvard Medical School (Post doctoral fellowship); University of Saskatchewan (Doctor of Philosophy (Ph.D.), Pharmacology).

Same school

Shared employers